VCELVericel Corporation

$2B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$58M+27.0% YoY

Gross Profit

$42M71.9% margin

Operating Income

-$2M-4.3% margin

Net Income

-$901,000-1.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

+10.0%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

$41M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$390M

Total Liabilities

$133M

Stockholders' Equity

$257M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$58M	$46M	+27.0%
Gross Profit	$42M	$31M	+36.1%
Operating Income	-$2M	-$5M	+51.3%
Net Income	-$901,000	-$4M	+75.4%

Revenue Segments

MACI Implants And Kits

$45M100%

VCEL Q3 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena